The chloroquine products market was valued at USD 510.1 Mn by 2019. The rising prevalence of protozoan infection worldwide primarily drives the chloroquine product's market growth. Furthermore increasing clinical trial investigation highlighting positive therapeutic efficacy for the treatment of autoimmune diseases will further accentuate the chloroquine products market growth.

Chloroquine was developed in the early 1940s as an aminoquinolone derivative for the treatment of malaria. It is a broad-spectrum drug that is also utilized for the treatment of all strains of plasmodium infection throughout the globe and also as a prophylactic agent in the treatment of the Zika virus. It exerts its pharmacological effect by inhibiting the action of heme polymerase which eventually results in the buildup of toxic heme in the plasmodium species.

The major segments related to the chloroquine products market are: 

By Clinical Application (2017–2027; US$ Mn)

Protozoan Infection

Autoimmune Diseases

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global chloroquine products market
• The overall segmentation of the chloroquine products market, by clinical application, distribution channel, and geography is minutely studied. Protozoan infection and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
• Growing incidence of protozoan infection worldwide
• Positive clinical studies data suggest the therapeutic efficacy of chloroquine in the treatment of autoimmune disease further accentuates the market growth

Report gist?

• The study of the global chloroquine products market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of chloroquine products due to the growing incidence of protozoan infection worldwide
• The report will researchers engaged in the development of chloroquine products drug formulation for the treatment of autoimmune diseases
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to chloroquine products market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Protozoan infection is representing the largest market share in the clinical application segment for the chloroquine products market. As per the latest research citings provided by the World Health Organization (WHO) in 2018, approximately 228 million cases of malaria infection were reported worldwide. North Africa, South East Asia, and Amazon rain forests are the hotspot for malaria infection, where lack of awareness is associated with a high mortality rate associated with malarial infection. Amebiasis is the second largest cause of death associated with a parasitic infection, eventually causing the death of 100,000 people throughout the globe each year. Autoimmune disease is keen to record exemplary market growth in the near future on account of the growing incidence of rheumatoid arthritis worldwide. According to the latest statistics provided by the National Institute of Health (NIH), the annual incidence rate of rheumatoid arthritis is 3 cases per 10,000 people worldwide.

Hospital pharmacy is currently dominating the distribution channel segment for the chloroquine products market. The drug is associated with high degree cellular toxicity and hence precise compounding by hospital pharmacists in accordance with doctor’s prescription is mandatory to avoid fatal outcomes. Retail pharmacy is expected to register excellent market growth during the forecast period majorly due to flourishing generic drugs market in the developing regions and the ability to provide affordable medication to people residing in remote locations.

Asia Pacific is presently leading the geography segment for the chloroquine products market. The rising prevalence of protozoan infection in the South East Asia region primarily drives the market growth. Topical weather and monsoon climate provide teeming grounds for malarial and amoebiasis parasites, hence it increases the demand for chloroquine products market. Furthermore, the flourishing generic drug market further propels the chloroquine products market. Latin America holds the second-largest market share in the regional segment chiefly due to rising public health awareness resulting in early screening and treatment for protozoan infection and rising prevalence of malaria infection in the amazon rain forest. North America is anticipated to be the fastest-growing regional segment for the chloroquine products market. Affordable reimbursement scenario and supportive regulatory environment provided by the USFDA for the sale and distribution of chloroquine products drive the market growth in the region.